FBLG
FibroBiologics, Inc.Company Information
- Company Name
- FibroBiologics, Inc.
- CIK
- CIK0001958777
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- FBLG: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- FBLG
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-04
- Last sale
- —
- Shares purchased (TTM)
- 315,872
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 284,937
- Shares outstanding
- 6,272,541
- Ownership
- 4.54%
Earnings Market Reaction
- Filing date
- 2026-07-31
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 4 | 1 | 5 | 5 | 9 | 9 | 14 | 8 | 6 | 8 | 9 | ||||||
Assets Current | |||||||||||||||||
| Assets Current | 6 | 3 | 6 | 5 | 10 | 9 | 14 | 8 | 7 | 9 | 9 | ||||||
| Prepaid Expense Current | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||||||
| Other Assets Current | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 2 | 2 | 3 | 3 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Other Assets | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | ||||||
| Assets | 8 | 6 | 10 | 9 | 14 | 11 | 16 | 10 | 9 | 11 | 12 | ||||||
Liabilities And Stockholders Equity | |||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 2 | 1 | 1 | 1 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Current | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | |||||||||||||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | 0 | 2 | - | - | ||||||
| Liabilities Current | 2 | 2 | 2 | 7 | 11 | 8 | 13 | 7 | 10 | 14 | 9 | ||||||
| Notes Payable Current | - | - | 0 | 5 | 8 | 6 | 9 | 0 | 0 | 0 | - | ||||||
| Loans Payable Current | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 3 | 3 | 3 | 9 | 13 | 9 | 14 | 8 | 11 | 15 | 11 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | ||||||
Stockholders Equity | |||||||||||||||||
| Stockholders Equity | 5 | 3 | 6 | 0 | 1 | 2 | 3 | 3 | -2 | -4 | 1 | ||||||
| Additional Paid In Capital | 68 | 62 | 60 | 51 | 46 | 43 | 38 | 35 | 30 | 29 | 26 | ||||||
| Retained Earnings Accumulated Deficit | -63 | -59 | -54 | -51 | -45 | -40 | -36 | -32 | -32 | -33 | -24 | ||||||
| Liabilities And Stockholders Equity | 8 | 6 | 10 | 9 | 14 | 11 | 16 | 10 | 9 | 11 | 12 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 | 20 | 20 | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 100 | 100 | - | - | - | - | ||||||
| Stockholders Equity Note Stock Split Conversion Ratio1 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialFibroBiologics, Inc. (FBLG) — SEC Financial Statements & Analysis
FibroBiologics, Inc. (FBLG) is a pharmaceutical preparations company, incorporated in DE. FibroBiologics, Inc. trades on Nasdaq as: FBLG. FibroBiologics, Inc. (FBLG)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-31. Based on that filing, FibroBiologics, Inc. carries a market cap of $5.95M, a P/E ratio of -0.33x, a P/B ratio of 1.28x, an enterprise value of $2.56M, and an EV/EBITDA multiple of -0.16x. On profitability, it posts a Return on Equity (ROE) of -660.08%, a Return on Assets (ROA) of -166.14%, and a Return on Invested Capital (ROIC) of -2523.23%. Per share, it reports EPS of $-2.89, diluted EPS of $-2.89, free cash flow per share of $-2.36, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 37.18% year-over-year and EPS growth of -57.75% year-over-year. On the balance sheet, it maintains a current ratio of 2.64x, a quick ratio of 2.40x, working capital of $3.64M, a debt-to-equity ratio of 0.71x, a debt ratio of 0.42, an interest coverage ratio of -77.81x, free cash flow of $-14.80M (TTM), and net debt of $-3.39M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.95M
- P/E TTM
- -0.33x
- EPS TTM
- $-2.89
- P/B TTM
- 1.28x
- ROE TTM
- -660.08%
- ROA TTM
- -166.14%
- Debt To Equity
- 0.71x
- Free Cash Flow TTM
- $-14.80M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is FibroBiologics, Inc. in?
FibroBiologics, Inc. (FBLG) operates in the Pharmaceutical Preparations industry.
What exchange does FBLG trade on?
FibroBiologics, Inc. (FBLG) trades on the Nasdaq.
Where is FibroBiologics, Inc. incorporated?
FibroBiologics, Inc. is incorporated in DE.
When was FibroBiologics, Inc. (FBLG)'s most recent SEC filing?
FibroBiologics, Inc. (FBLG)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-31.
What is FBLG's market cap?
FibroBiologics, Inc. (FBLG) has a market capitalization of $5.95M as of 2026-06-30.
What is FBLG's EPS (earnings per share)?
FibroBiologics, Inc. (FBLG)'s trailing twelve month EPS is $-2.89 as of 2026-06-30.
What is FBLG's ROE (return on equity)?
FibroBiologics, Inc. (FBLG)'s trailing twelve month Return on Equity (ROE) is -660.08% as of 2026-06-30.
What is FBLG's ROA (return on assets)?
FibroBiologics, Inc. (FBLG)'s trailing twelve month Return on Assets (ROA) is -166.14% as of 2026-06-30.
What is FBLG's ROIC (return on invested capital)?
FibroBiologics, Inc. (FBLG)'s trailing twelve month Return on Invested Capital (ROIC) is -2523.23% as of 2026-06-30.
What is FBLG's EV/EBITDA?
FibroBiologics, Inc. (FBLG)'s trailing twelve month EV/EBITDA is -0.16x as of 2026-06-30.